Altaf S A, Yu K, Parasrampuria J, Friend D R
CIBUS Pharmaceutical, Inc., Menlo Park, California 94026-1226, USA.
Pharm Res. 1998 Aug;15(8):1196-201. doi: 10.1023/a:1011931622536.
This study was performed to examine the use of guar gum to sustain the release of diltiazem under in vitro and in vivo conditions.
Guar gum tablet formulations were prepared and evaluated under a variety of in vitro dissolution conditions. The formulations, along with Dilacor XR, were administered to a group eight fasted, healthy volunteers in a four period crossover study.
Varying the lot of guar gum as well as using guar from different suppliers had little effect on diltiazem dissolution. Also, dissolution of diltiazem from guar gum tablets was essentially independent of stir speed under normal conditions (USP Apparatus II) The stability of guar-based formulations under stressed conditions (40 degrees C/75% relative humidity for 3 months) was also established. All four formulations gave similar plasma concentrations over time in the healthy volunteers pharmacokinetic study.
Guar gum-based matrix tablets represent a simple and economical alternative to existing diltiazem sustained release dosage forms.
本研究旨在考察瓜尔胶在体外和体内条件下对缓释地尔硫䓬的作用。
制备瓜尔胶片剂制剂,并在多种体外溶出条件下进行评价。在一项为期四个阶段的交叉研究中,将这些制剂与Dilacor XR一起给予一组八名禁食的健康志愿者。
改变瓜尔胶的批次以及使用不同供应商的瓜尔胶对地尔硫䓬的溶出影响很小。此外,在正常条件下(美国药典装置II),地尔硫䓬从瓜尔胶片剂中的溶出基本与搅拌速度无关。还确定了瓜尔胶基制剂在加速条件下(40℃/75%相对湿度,3个月)的稳定性。在健康志愿者的药代动力学研究中,所有四种制剂随时间推移给出了相似的血浆浓度。
瓜尔胶基骨架片是现有地尔硫䓬缓释剂型的一种简单且经济的替代剂型。